Reblozyl (luspatercept-aamt) - BMS, Merck (MSD)
Epogen (epoetin alfa) - Amgen
emavusertib (CA-4948) - Curis
Eprex (epoetin alfa) - J&J
Retacrit (epoetin alfa-epbx) - Stada, Norbitec, Pfizer
A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov) - Sep 10, 2026 - P2 | N=270 | Not yet recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jun 2026 ➔ Sep 2026 
Trial initiation date • Anemia • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Myelodysplastic Syndrome • Oncology
http://clinicaltrials.gov/ct2/show/NCT07463820
 
Sep 10, 2026
 
Prev Next